Compare TRMK & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRMK | ARQT |
|---|---|---|
| Founded | 1889 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1994 | 2020 |
| Metric | TRMK | ARQT |
|---|---|---|
| Price | $42.93 | $21.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $44.50 | $34.00 |
| AVG Volume (30 Days) | 292.5K | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | 1.93 | ★ 88.79 |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $9.82 | $34.85 |
| Revenue Next Year | $4.86 | $29.39 |
| P/E Ratio | $46.26 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $33.39 | $12.72 |
| 52 Week High | $45.99 | $31.77 |
| Indicator | TRMK | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 46.38 |
| Support Level | $38.73 | $21.12 |
| Resistance Level | $43.29 | $21.95 |
| Average True Range (ATR) | 0.87 | 0.84 |
| MACD | -0.12 | 0.13 |
| Stochastic Oscillator | 8.47 | 59.75 |
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.